Tumour suppressor function of RNase L in a mouse model

European Journal of Cancer

Volumn 43, Issue 1, 2007, Pages 202-209

  Liu, Wendy ^a,b   Liang, Shu Ling ^b,c   Liu, Hongli ^a,b   Silverman, Robert ^b,d   Zhou, Aimin ^a,b,d  

^a CLEVELAND STATE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bone marrow; Fibrosarcoma; GM CSF; Interferon; RNase L

Indexed keywords

COMPLEMENTARY DNA; INTERFERON; RIBONUCLEASE L;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOLOGY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; EXPRESSION VECTOR; FIBROSARCOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DNA, COMPLEMENTARY; ENDORIBONUCLEASES; FIBROSARCOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION;

EID: 33845999930     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.08.024     Document Type: Article

References (24)

1. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu Rev Biochem 67 (1998) 227-264
2. Kerr I.M., and Brown R.E. pppA2′p5′A2′p5′A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. Proc Natl Acad Sci USA 75 1 (1978) 256-260
3. Hovanessian A.G., Brown R.E., and Kerr I.M. Synthesis of low molecular weight inhibitor of protein synthesis with enzyme from interferon-treated cells. Nature 268 (1977) 537-539
4. Chebath J., Benech P., hovanessian A., Galabru J., and Revel M. Four different forms of interferon-induced 2-5 oligoA synthetase identified by immunoblotting in human cells. J Biol Chem 262 (1978) 3852-3857
5. Zhou A., Paranjape J.M., Hassel B.A., et al. Impact of RNase L overexpression on viral and cellular growth and death. J Interferon Cytokine Res 18 11 (1998) 953-961
6. Hassel B.A., Zhou A., Sotomayor C., Maran A., and Silverman R.H. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J 12 (1993) 3297-3304
7. Zhou A., Paranjape J., Brown T.L., et al. Interferon action and apoptosis are defective in mice devoid of 2′,5′-oligoadenylate-dependent RNase L. EMBO J 16 21 (1997) 6355-6363
8. Silverman R.H. 2-5A dependent RNase L: a regulated endoribonuclease in the interferon system. In: D'alessio G., and Riordan J.F. (Eds). Ribonucleases: structure and function (1996), Academic Press Inc., New York 517-547
9. Rusch L., Zhou A., and Silverman R.H. Caspase-dependent apoptosis by 2′,5′-oligoadenylate activation of RNase L is enhanced by IFN-beta. J Interferon Cytokine Res 20 12 (2000) 1091-1100
10. Castelli J.C., Hassel B.A., Maran A., et al. The role of 2′-5′ oligoadenylate-activated ribonuclease L in apoptosis. Cell Death Differ 5 4 (1998) 313-320
11. Castelli J.C., Hassel B.A., Wood K.A., et al. A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. J Exp Med 186 6 (1997) 967-972
12. Li G., Xiang Y., Sabapathy K., and Silverman R.H. An apoptotic signaling pathway in the interferon antiviral response mediated by RNase L and c-Jun NH2-terminal kinase. J Biol Chem 279 2 (2004) 1123-1131
13. Carpten J., Nupponen N., Isaacs S., et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nature Genet 30 (2002) 181-184
14. Wang L., McDonnell S.K., Elkins D.A., et al. Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet 71 1 (2002) 116-123
15. Rokman A., Ikonen T., Seppala E.H., et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 70 5 (2002) 1299-1304
16. Casey G., Neville P.J., Plummer S.J., et al. RNASEL ARG462GLN variant is implicated in up to 13% of prostate cancer cases. Nature Genet 32 (2002) 581-583
17. Zhou A., Paranjape J.M., Der S.D., Williams B.R., and Silverman R.H. Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. Virology 258 (1999) 435-440
18. Silverman R.H. Implications for RNase L in prostate cancer biology. Biochemistry 42 (2003) 1805-1812
19. Li X.L., Blackford J.A., Judge C.S., et al. RNase-L-dependent destabilization of interferon-induced mRNAs. A role for the 2-5A system in attenuation of the interferon response. J Biol Chem 275 12 (2000) 8880-8888
20. Khabar K.S., Siddiqui Y.M., Al-Zoghaibi F., et al. RNase L mediates transient control of interferon response through modulation of the double-stranded RNA dependent protein kinase PKR. J Biol Chem 278 22 (2003) 20124-20132
21. Bisbal C., Silhol M., Laubenthal H., et al. The 2′-5′ oligoadenylate/RNase L/RNase L inhibitor pathway regulates both MyoD mRNA stability and muscle cell differentiation. Mol Cell Biol 20 14 (2000) 4959-4969
22. Le Roy F., Bisbal C., Silhol M., Martinand C., Lebleu B., and Salehzada T. The 2-5A/RNase L/RNase L inhibitor (RLI) [correction of (RNI)] pathway regulates mitochondrial mRNAs stability in interferon alpha-treated H9 cells. J Biol Chem 276 51 (2001) 48473-48482
23. Le Roy F., Salehzada T., Bisbal C., Dougherty J.P., and Peltz S.W. A newly discovered function for RNase L in regulating translation termination. Nat Struct Mol Biol 12 6 (2005) 505-512
24. Xia Y., and Karin M. The control of cell motility and epithelial morphogenesis by Jun kinases. Trends Cell Biol 14 (2004) 94-101